CA2868684A1 - Nanoparticle aggregates containing osteopontin and calcium-and/or strontium-containing particles - Google Patents
Nanoparticle aggregates containing osteopontin and calcium-and/or strontium-containing particles Download PDFInfo
- Publication number
- CA2868684A1 CA2868684A1 CA2868684A CA2868684A CA2868684A1 CA 2868684 A1 CA2868684 A1 CA 2868684A1 CA 2868684 A CA2868684 A CA 2868684A CA 2868684 A CA2868684 A CA 2868684A CA 2868684 A1 CA2868684 A1 CA 2868684A1
- Authority
- CA
- Canada
- Prior art keywords
- nanoparticle aggregates
- spp
- opn
- biofilm
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000002105 nanoparticle Substances 0.000 title claims abstract description 187
- 102000004264 Osteopontin Human genes 0.000 title claims abstract description 186
- 108010081689 Osteopontin Proteins 0.000 title claims abstract description 186
- 239000002245 particle Substances 0.000 title claims abstract description 90
- 229910052712 strontium Inorganic materials 0.000 title claims abstract description 60
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 title claims abstract description 44
- 239000011575 calcium Substances 0.000 claims abstract description 65
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 60
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 44
- 230000012010 growth Effects 0.000 claims abstract description 38
- 201000010099 disease Diseases 0.000 claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 26
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 62
- 239000001506 calcium phosphate Substances 0.000 claims description 61
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 61
- 235000011010 calcium phosphates Nutrition 0.000 claims description 61
- 229910019142 PO4 Inorganic materials 0.000 claims description 49
- 230000001580 bacterial effect Effects 0.000 claims description 26
- 230000000813 microbial effect Effects 0.000 claims description 26
- 241000894006 Bacteria Species 0.000 claims description 23
- 208000002925 dental caries Diseases 0.000 claims description 19
- 239000010452 phosphate Substances 0.000 claims description 16
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 16
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 14
- 241000186046 Actinomyces Species 0.000 claims description 11
- 241000194017 Streptococcus Species 0.000 claims description 11
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 9
- 208000035143 Bacterial infection Diseases 0.000 claims description 8
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 8
- 241000894007 species Species 0.000 claims description 7
- 208000007565 gingivitis Diseases 0.000 claims description 6
- 206010048038 Wound infection Diseases 0.000 claims description 5
- 241001024600 Aggregatibacter Species 0.000 claims description 4
- 241000589876 Campylobacter Species 0.000 claims description 4
- 208000002064 Dental Plaque Diseases 0.000 claims description 4
- 241000186660 Lactobacillus Species 0.000 claims description 4
- 241000186781 Listeria Species 0.000 claims description 4
- 241000605894 Porphyromonas Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 229940039696 lactobacillus Drugs 0.000 claims description 4
- 201000001245 periodontitis Diseases 0.000 claims description 4
- 241001148536 Bacteroides sp. Species 0.000 claims description 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 3
- 206010064687 Device related infection Diseases 0.000 claims description 3
- 241000588877 Eikenella Species 0.000 claims description 3
- 206010014666 Endocarditis bacterial Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 241000605861 Prevotella Species 0.000 claims description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 3
- 241000589886 Treponema Species 0.000 claims description 3
- 208000009361 bacterial endocarditis Diseases 0.000 claims description 3
- 230000001684 chronic effect Effects 0.000 claims description 3
- 201000007119 infective endocarditis Diseases 0.000 claims description 3
- 208000025157 Oral disease Diseases 0.000 claims description 2
- 208000030194 mouth disease Diseases 0.000 claims description 2
- 241000606125 Bacteroides Species 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 110
- 229910001868 water Inorganic materials 0.000 description 83
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 229910052708 sodium Inorganic materials 0.000 description 22
- 229910052700 potassium Inorganic materials 0.000 description 18
- 229910052725 zinc Inorganic materials 0.000 description 18
- 229910052788 barium Inorganic materials 0.000 description 16
- 229910052749 magnesium Inorganic materials 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 229910052792 caesium Inorganic materials 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 229910052701 rubidium Inorganic materials 0.000 description 15
- JOPDZQBPOWAEHC-UHFFFAOYSA-H tristrontium;diphosphate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O JOPDZQBPOWAEHC-UHFFFAOYSA-H 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 229910052790 beryllium Inorganic materials 0.000 description 14
- 229910052744 lithium Inorganic materials 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000002178 crystalline material Substances 0.000 description 11
- 101100518498 Bos taurus SPP1 gene Proteins 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 239000011521 glass Substances 0.000 description 10
- 235000013336 milk Nutrition 0.000 description 10
- 239000008267 milk Substances 0.000 description 10
- 210000004080 milk Anatomy 0.000 description 10
- 238000002441 X-ray diffraction Methods 0.000 description 8
- 230000003214 anti-biofilm Effects 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 238000002411 thermogravimetry Methods 0.000 description 8
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- 230000032770 biofilm formation Effects 0.000 description 7
- 239000003792 electrolyte Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 210000000214 mouth Anatomy 0.000 description 7
- 239000002159 nanocrystal Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 241000283690 Bos taurus Species 0.000 description 6
- 239000008199 coating composition Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 239000004793 Polystyrene Substances 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229920002223 polystyrene Polymers 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000186045 Actinomyces naeslundii Species 0.000 description 4
- 238000003991 Rietveld refinement Methods 0.000 description 4
- 241001134658 Streptococcus mitis Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 230000000877 morphologic effect Effects 0.000 description 4
- 239000002324 mouth wash Substances 0.000 description 4
- 210000004898 n-terminal fragment Anatomy 0.000 description 4
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000193992 Streptococcus downei Species 0.000 description 3
- 241000194025 Streptococcus oralis Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 229910052586 apatite Inorganic materials 0.000 description 3
- 230000010065 bacterial adhesion Effects 0.000 description 3
- 229940112822 chewing gum Drugs 0.000 description 3
- 235000015218 chewing gum Nutrition 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- PWYYWQHXAPXYMF-UHFFFAOYSA-N strontium(2+) Chemical compound [Sr+2] PWYYWQHXAPXYMF-UHFFFAOYSA-N 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 239000000606 toothpaste Substances 0.000 description 3
- 239000002966 varnish Substances 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010006326 Breath odour Diseases 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 2
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 2
- 208000006558 Dental Calculus Diseases 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 2
- 102100030277 Secreted phosphoprotein 24 Human genes 0.000 description 2
- 241000775112 Streptococcus sanguinis SK150 Species 0.000 description 2
- 102000012005 alpha-2-HS-Glycoprotein Human genes 0.000 description 2
- 108010075843 alpha-2-HS-Glycoprotein Proteins 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 150000001449 anionic compounds Chemical class 0.000 description 2
- 230000002272 anti-calculus Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 238000007654 immersion Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229910001412 inorganic anion Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 102000043253 matrix Gla protein Human genes 0.000 description 2
- 108010057546 matrix Gla protein Proteins 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000028169 periodontal disease Diseases 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108010079711 secreted phosphoprotein 24 Proteins 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 2
- 235000019801 trisodium phosphate Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 1
- 241000606749 Aggregatibacter actinomycetemcomitans Species 0.000 description 1
- 235000002198 Annona diversifolia Nutrition 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 101000741065 Bos taurus Beta-casein Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000589996 Campylobacter rectus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000186031 Corynebacteriaceae Species 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- 102100022375 Dentin matrix acidic phosphoprotein 1 Human genes 0.000 description 1
- 101710105839 Dentin matrix acidic phosphoprotein 1 Proteins 0.000 description 1
- 241000588878 Eikenella corrodens Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000947120 Homo sapiens Beta-casein Proteins 0.000 description 1
- 101001123943 Human cytomegalovirus (strain AD169) Large structural phosphoprotein Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241000282838 Lama Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101100365384 Mus musculus Eefsec gene Proteins 0.000 description 1
- 206010065233 Oral bacterial infection Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108010001441 Phosphopeptides Proteins 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241001135221 Prevotella intermedia Species 0.000 description 1
- 241001135225 Prevotella nigrescens Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 241000194023 Streptococcus sanguinis Species 0.000 description 1
- 101150101561 TOM70 gene Proteins 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 206010044029 Tooth deposit Diseases 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 125000000129 anionic group Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 239000006161 blood agar Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000004075 cariostatic agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 210000001315 dental pellicle Anatomy 0.000 description 1
- 210000004262 dental pulp cavity Anatomy 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- CGMRCMMOCQYHAD-UHFFFAOYSA-J dicalcium hydroxide phosphate Chemical compound [OH-].[Ca++].[Ca++].[O-]P([O-])([O-])=O CGMRCMMOCQYHAD-UHFFFAOYSA-J 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000002707 nanocrystalline material Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 101150115693 ompA gene Proteins 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 101150090944 otomp gene Proteins 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108010053455 riboflavin-binding protein Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0241—Containing particulates characterized by their shape and/or structure
- A61K8/0275—Containing agglomerated particulates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Physiology (AREA)
- Dispersion Chemistry (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12161802 | 2012-03-28 | ||
| EP12161802.9 | 2012-03-28 | ||
| PCT/EP2013/056598 WO2013144247A1 (en) | 2012-03-28 | 2013-03-27 | Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2868684A1 true CA2868684A1 (en) | 2013-10-03 |
Family
ID=48141914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2868684A Abandoned CA2868684A1 (en) | 2012-03-28 | 2013-03-27 | Nanoparticle aggregates containing osteopontin and calcium-and/or strontium-containing particles |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20150044260A1 (https=) |
| EP (1) | EP2830647A1 (https=) |
| JP (1) | JP2015516949A (https=) |
| KR (1) | KR20150004814A (https=) |
| CN (1) | CN104321073A (https=) |
| AR (1) | AR090569A1 (https=) |
| AU (1) | AU2013241750A1 (https=) |
| CA (1) | CA2868684A1 (https=) |
| CL (1) | CL2014002583A1 (https=) |
| EA (1) | EA201491691A1 (https=) |
| MX (1) | MX2014011594A (https=) |
| NZ (1) | NZ700295A (https=) |
| WO (1) | WO2013144247A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5548121B2 (ja) | 2007-05-14 | 2014-07-16 | リサーチ ファウンデーション オブ ステイト ユニバーシティ オブ ニューヨーク | バイオフィルム中の細菌細胞における生理学的分散応答の誘導 |
| US12109284B2 (en) | 2016-11-08 | 2024-10-08 | Dentherapy Ltd | Compositions comprising fluoride and calcium and method for preparing them |
| US11541105B2 (en) | 2018-06-01 | 2023-01-03 | The Research Foundation For The State University Of New York | Compositions and methods for disrupting biofilm formation and maintenance |
| US20220183933A1 (en) * | 2019-03-22 | 2022-06-16 | The Board Of Regents Of The University Of Oklahoma | Surface-modified doped titanium dioxide nanoparticles and uses |
| CN111366733B (zh) * | 2020-03-07 | 2022-02-08 | 浙江大学 | 骨桥蛋白作为靶分子在调节肠道菌群定植中的应用 |
| EP4129413A4 (en) * | 2020-03-27 | 2024-04-24 | NOF Corporation | Composition for oral cavity |
| GB202010987D0 (en) | 2020-07-16 | 2020-09-02 | Dentherapy Ltd | Oral care compositions and methods |
| GB202110114D0 (en) | 2021-07-14 | 2021-08-25 | Dentherapy Ltd | Oral care compositions for use in treaatment |
| WO2023187028A1 (en) * | 2022-03-31 | 2023-10-05 | Nadavia Holding Aps | Mouthwash composition comprising one or more strontium salt |
| WO2025008636A1 (en) | 2023-07-06 | 2025-01-09 | Dentherapy Ltd | Oral care compositions for use in the treatment of dental health conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7259243B2 (en) * | 2000-01-07 | 2007-08-21 | Arla Foods Amba | Process for isolation of osteopontin from milk |
| NZ507335A (en) | 2000-10-05 | 2004-10-29 | New Zealand Dairy Board | Bone health compositions derived from milk comprising an acidic protein fraction but that does not contain CGMP |
| CN1889922B (zh) | 2003-12-01 | 2010-11-24 | 阿尔拉食品公司 | 骨桥蛋白在牙用制剂中的用途 |
| EA200870058A1 (ru) * | 2005-12-16 | 2008-12-30 | Арла Фудс Амба | Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран |
| EP2175841A1 (en) * | 2007-07-16 | 2010-04-21 | Aarhus Universitet | Osteopontin nanoparticles system for drug delivery |
| AU2012222312B2 (en) | 2011-03-03 | 2017-06-08 | Arla Foods Amba | Method for isolating osteopontin using feeds containing cmp or casein species |
-
2013
- 2013-03-27 MX MX2014011594A patent/MX2014011594A/es unknown
- 2013-03-27 CA CA2868684A patent/CA2868684A1/en not_active Abandoned
- 2013-03-27 US US14/387,946 patent/US20150044260A1/en not_active Abandoned
- 2013-03-27 JP JP2015502339A patent/JP2015516949A/ja active Pending
- 2013-03-27 EP EP13717196.3A patent/EP2830647A1/en not_active Withdrawn
- 2013-03-27 NZ NZ700295A patent/NZ700295A/en not_active IP Right Cessation
- 2013-03-27 AU AU2013241750A patent/AU2013241750A1/en not_active Abandoned
- 2013-03-27 KR KR1020147029790A patent/KR20150004814A/ko not_active Withdrawn
- 2013-03-27 WO PCT/EP2013/056598 patent/WO2013144247A1/en not_active Ceased
- 2013-03-27 EA EA201491691A patent/EA201491691A1/ru unknown
- 2013-03-27 CN CN201380025647.3A patent/CN104321073A/zh active Pending
- 2013-04-03 AR ARP130101064A patent/AR090569A1/es unknown
-
2014
- 2014-09-26 CL CL2014002583A patent/CL2014002583A1/es unknown
-
2016
- 2016-04-05 US US15/091,499 patent/US20170065673A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014011594A (es) | 2015-07-06 |
| US20170065673A1 (en) | 2017-03-09 |
| EA201491691A1 (ru) | 2015-04-30 |
| WO2013144247A1 (en) | 2013-10-03 |
| JP2015516949A (ja) | 2015-06-18 |
| CN104321073A (zh) | 2015-01-28 |
| AU2013241750A8 (en) | 2014-10-23 |
| US20150044260A1 (en) | 2015-02-12 |
| KR20150004814A (ko) | 2015-01-13 |
| AU2013241750A1 (en) | 2014-10-09 |
| EP2830647A1 (en) | 2015-02-04 |
| NZ700295A (en) | 2016-07-29 |
| AR090569A1 (es) | 2014-11-19 |
| CL2014002583A1 (es) | 2015-06-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170065673A1 (en) | Nanoparticle aggregates containing osteopontin and calcium- and/or strontium-containing particles | |
| JP7058344B2 (ja) | 歯肉健康を促進するための口腔ケア組成物 | |
| JP7058343B2 (ja) | 歯肉健康を促進するための口腔ケア組成物 | |
| JP7058342B2 (ja) | 歯肉健康を促進するための口腔ケア組成物 | |
| Kovtun et al. | Chlorhexidine-loaded calcium phosphate nanoparticles for dental maintenance treatment: combination of mineralising and antibacterial effects | |
| Abdelnabi et al. | Effect of different formulations and application methods of coral calcium on its remineralization ability on carious enamel | |
| JP5973585B2 (ja) | ラクトフェリン機能化表面を有する生体模倣ヒドロキシアパタイト粒子を含有するデンタルケア製品 | |
| Cordero et al. | Li-doped bioglass® 45S5 for potential treatment of prevalent oral diseases | |
| Uskoković et al. | Synthesis and characterization of nanoparticulate niobium-and zinc-doped bioglass-ceramic/chitosan hybrids for dental applications | |
| Roveri et al. | Recent advancements in preventing teeth health hazard: the daily use of hydroxyapatite instead of fluoride | |
| BRPI0618143A2 (pt) | uso de sais de cálcio dificilmente hidrossolúveis e/ou seus compósitos | |
| Yang et al. | Injectable hydrogels activated with copper sulfide nanoparticles for enhancing spatiotemporal sterilization and osteogenesis in periodontal therapy | |
| RU2722306C1 (ru) | Композиция для регуляции микроэлементного обмена в полости рта | |
| Babayevska et al. | Novel nanosystems to enhance biological activity of hydroxyapatite against dental caries | |
| WO2012036645A2 (en) | Preparation method of an oral care gel containing eggshell powder | |
| Lu et al. | Applications of photothermally mediated nanohybrids for white spot lesions in orthodontics | |
| Yan et al. | In vitro evaluation of a novel fluoride-coated clear aligner with antibacterial and enamel remineralization abilities | |
| Niu et al. | Efficacy of the dual-action GA-KR12 peptide for remineralising initial enamel caries: An in vitro study | |
| Xu et al. | VMT/ACP/Dextran composite nanosheets against dental caries through promoting mineralization of dentin tubules, pH buffering, and antibacterial | |
| KR101352795B1 (ko) | 치아의 접합능을 향상시키기 위한 치과용 클린저 조성물 | |
| Madhubala et al. | Evaluation of enamel remineralization potential and anticariogenic efficacy of polydopamine coated biogenic amorphous calcium phosphate | |
| CN105287244A (zh) | 蒙脱石功能性牙膏及其制备方法 | |
| Tabari et al. | The Effect of Silicone Oil and Nano-hydroxyapatite/Chitosan Powder on Microhardness and Surface Structure of Primary Teeth Enamel After Iron Drop Consumption. | |
| Shakir et al. | Innovation of nano-hydrogels loaded with amelogenin peptide and hydroxyapatite nano-particles for remineralisation of artificially induced white spot lesions | |
| DE102005052371A1 (de) | Verwendung von schwer wasserlöslichen Calciumsalzen und/oder deren Kompositen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20180327 |